Psilocybin for OCD: What the Research Shows

In October 2026, the Johns Hopkins Center for Psychedelic and Consciousness Research posted results from a trial of psilocybin for obsessive-compulsive disorder. Symptoms dropped substantially and stayed down a month later. Three other research groups have reported something similar since mid-2025.

That’s worth paying attention to. It’s also worth reading carefully, because every one of these studies is small, and the people in them had already tried the treatments that work for most people with OCD. Below is what each study found, what they have in common, and what none of them tells you yet.

The short answer

Psilocybin looks promising for OCD that hasn’t responded to standard treatment, and the evidence is still early. Four research groups (Johns Hopkins, the University of Arizona, Yale, and a UK team from the University of Hertfordshire and Imperial College London) have now reported symptom improvement, and psilocybin was well tolerated in all of them. But the largest of these studies analyzed 30 people, the newest one hasn’t been peer reviewed yet, and only one small trial compared psilocybin directly against a placebo for the full treatment period.

Exposure and Response Prevention (ERP) is still the first-line treatment for OCD, with decades of controlled trials behind it. Nearly everyone in the psilocybin studies had already tried ERP, medication, or both. The research question is whether psilocybin can help people those treatments didn’t, not whether it should replace them.

The new Johns Hopkins study

The Johns Hopkins preprint (Tiwari, Yaden, and colleagues, posted October 2026) enrolled 37 adults with OCD who had not improved with medication or evidence-based therapy such as ERP. Participants were randomly assigned to start right away or wait eight weeks. Everyone eventually received two psilocybin sessions two weeks apart, 20mg and then 30mg if the first dose was well tolerated, with supportive preparation and follow-up.

What it found. OCD severity, measured by clinicians using the standard Yale-Brown Obsessive Compulsive Scale (Y-BOCS), dropped more in the group treated right away than in the group still waiting. After both groups had been treated, the improvement held at the one-month follow-up. The effect sizes were large. People who reported stronger mystical-type experiences during their sessions tended to improve more.

What it can’t tell us. It’s a preprint, which means it hasn’t been through peer review. Everyone knew whether they’d received psilocybin, and so did the people rating their symptoms, so expectation could account for part of the result. The waiting group is a weak comparison, since a group that knows treatment is coming can’t stand in for a placebo. Thirty of the 37 people randomized were included in the analysis. And one month is a short follow-up for a condition that tends to be chronic.

The studies that came before it

University of Arizona, 2006. The first modern study, published in the Journal of Clinical Psychiatry, gave nine people with OCD up to four single doses of psilocybin at different strengths. Every participant had a marked drop in symptoms during at least one session, ranging from 23% to 100%, and the improvement generally lasted past 24 hours. The study was designed to test safety, not long-term benefit. Its main contribution was showing that psilocybin could be given safely to people with OCD in a controlled setting.

University of Arizona, 2026. The same group’s randomized trial in the Journal of Psychopharmacology (March 2026) is the most rigorous OCD study so far, though also one of the smallest. Fifteen people were randomly assigned to four weekly sessions of high-dose psilocybin, low-dose psilocybin, or an active placebo (lorazepam), without knowing which they got. Then everyone received four more high-dose sessions. By the end of eight weeks, 73% met the standard criteria for a meaningful response and 40% were in remission. Benefits faded somewhat but remained substantial at six months. More total psilocybin went with more improvement. There were no serious adverse events, no psychotic symptoms, and no increase in suicidality. The catch: with only five people per group, the comparison against placebo during the blinded phase was not as clear-cut as the summary suggests.

University of Hertfordshire and Imperial College London, 2025. A UK study in Comprehensive Psychiatry gave 19 adults with OCD two doses four weeks apart: a 1mg dose that has almost no effect, then a 10mg dose, which is less than half the dose used in most psilocybin trials. Neither participants nor raters were told which dose came first. One week after the 10mg dose, OCD symptoms were meaningfully lower than after 1mg, mostly because compulsions dropped. The effect faded over the next three weeks. Psilocybin was well tolerated. The doses weren’t randomized, and the sample was small.

Yale, 2026. Yale has run a single-dose, placebo-controlled trial in people with treatment-resistant OCD, and two analyses from it were published in September 2026. They’re less about whether psilocybin works and more about who it seems to help. Both are described below.

More sessions, longer benefit

Put side by side, these studies suggest a pattern. One low dose (the UK study) helped for about a week. Two higher doses (Hopkins) held for at least a month. Up to eight doses (Arizona) held, though somewhat weaker, for six months, and more total psilocybin went with more improvement.

That isn’t a controlled comparison. The studies differ in dose, design, and who they enrolled. But it fits what researchers found in psilocybin trials for addiction, where repeated sessions with more therapy did better than a single dose. Nobody yet knows the right number of sessions for OCD, or how safe repeated dosing is over the long term.

Who seems to improve

The averages in these studies hide a wide range. Some participants improved dramatically, and others didn’t change. Researchers are starting to find out what separated them.

The kind of experience mattered. In an analysis of 27 Yale participants, stronger mystical-type experiences, such as feelings of unity, sacredness, and transcendence, predicted lower OCD severity at one and twelve weeks. Difficult or frightening experiences during the session did not predict worse outcomes. The Hopkins study found the same link with mystical-type experience. That pattern matches what has been found for depression and addiction (more in our post on the mystical experience).

Letting go seemed to matter more than intensity. A Yale interview study compared three participants who improved markedly with three who didn’t. The people who improved described surrendering during the session rather than trying to stay in control. Afterward, they felt more separate from their OCD, were kinder to themselves, and came to see their obsessive concerns as arbitrary and inconsequential. The people who didn’t improve either held on to control or found surrendering overwhelming, and they stayed convinced by OCD’s logic.

The researchers drew one distinction above the others: insight versus felt change. Participants who improved described insights they felt in their bodies, and those insights changed what they did. Participants who didn’t improve could often explain their OCD clearly but felt and acted the same.

Anyone who has done ERP will recognize that distinction. ERP doesn’t work by convincing you that your fears are irrational, which most people with OCD already know. It works by having you experience the feared situation without doing the compulsion, until your nervous system learns something your reasoning couldn’t teach it (more in what is Exposure and Response Prevention). The early psilocybin findings point to a similar mechanism reached by a different route. That’s an interesting overlap, not evidence that one can stand in for the other.

Why these studies are hard to read

They’re small. All five studies combined include only about 100 people treated with psilocybin. One or two new trials could change the picture a lot.

Blinding barely works. People almost always know whether they received psilocybin. Even the Arizona trial’s active placebo can’t fully hide the effects of a high dose. When people know they got the real drug, expectation can drive part of the result.

Participants are carefully screened. These trials generally excluded people with psychotic disorders, bipolar disorder, serious medical illness, and other conditions. Results in screened research volunteers don’t automatically apply to people with more complicated histories.

The protocols differ. Doses ranged from 10mg to 30mg, and from one session to eight. That makes the studies hard to pool, and it’s part of why the right protocol is still an open question.

Follow-up is short. The longest is six months. OCD often waxes and wanes over years, so we don’t know how long the benefit lasts or what happens when symptoms return.

Where this leaves ERP

If you have OCD and haven’t had a full course of ERP with a clinician trained in it, that’s still the place to start. ERP has the strongest evidence of any OCD treatment, including large randomized trials and long-term follow-up, and most people see meaningful improvement. Many people who think ERP “didn’t work” actually had general talk therapy, or exposures without real response prevention, which isn’t the same treatment. See our OCD treatment and CBT for OCD pages for what a full course looks like.

For people whose OCD comes with intense emotion, self-harm, or suicidal thinking that makes exposure hard to start, DBT for OCD can come before or alongside ERP.

The psilocybin research is about the people for whom those treatments haven’t been enough. That group is real and sizable. If you’re in it, the new studies are a genuine reason for hope, and a reason to keep following the research.

What this means in Colorado

Colorado’s natural medicine program is not the treatment that was studied in these trials, and it’s worth being precise about the difference.

The trials were medical research. Psilocybin was given by research teams that included physicians, with extensive screening, standardized symptom measurement, and structured support around each dose. Under the Natural Medicine Health Act, a licensed facilitator provides preparation, a supervised session, and integration. Facilitators are not prescribers, and a facilitated session is not, by itself, treatment for OCD.

What that means in practice:

Talk about medication with your prescriber first. OCD is often treated with higher doses of SSRIs than depression is, and whether to change any medication before a psilocybin session is a decision that belongs to you and your prescriber. Facilitators can’t direct a medication change. We cover both sides of that question in psilocybin and SSRIs. Programs generally rule out lithium and MAOIs. Other medications are a timing and coordination question.

Screening matters. Some histories that can come up alongside OCD, such as bipolar disorder or psychosis, call for real caution with psilocybin. See psilocybin contraindications for what licensed programs generally rule out and what needs a fuller conversation.

It works best alongside treatment, not instead of it. In every study above, psilocybin was added to support from clinicians, not given on its own. If you’re in ERP or another OCD treatment, keep your treating clinician in the loop.

Integration is where change has to take hold. The Yale findings suggest the difference between people who improved and people who didn’t came down to what they did with the experience: whether an insight became a change in behavior. That’s the work of integration, and it’s part of the service, not an optional extra.

The bottom line

Psilocybin for OCD is promising and early. Four independent research groups have reported meaningful improvement in people with OCD, most of whom hadn’t responded to standard treatment, and psilocybin was well tolerated in all of them. But the studies are small, mostly unblinded, short on follow-up, and in the newest case not yet peer reviewed.

ERP remains the first step. For people it hasn’t helped enough, this is a line of research worth following closely.

---

Considering natural medicine and living with OCD? Get in touch or book a free 15-minute consultation. We’ll talk through your history, including whether ERP or another therapy should come first. You may also want to read is psilocybin therapy right for you or learn about our natural medicine services.

This post is educational and is not medical advice. Psilocybin sessions under Colorado’s Natural Medicine Health Act are not a substitute for treatment of OCD. Don’t stop or change a psychiatric medication without talking to your prescriber.